Emmaus Life Sciences Inc (OTCMKTS:EMMA) Stock Jumps 10% In a Week: But Why?
Considering the sort of performance that the Emmaus Life Sciences Inc (OTCMKTS:EMMA) stock has delivered in the past week, it may now be the right time for investors to take a closer look at the company’s stock.
Market Stats
On Monday, EMMA stock fell 0.65% at $1.54 with more than 11.73k shares, compared to its average volume of 23.71k shares. The stock has moved within a range of $1.3100 – 1.5500 after opening trading at $1.53.
Emmaus Life Sciences’ Data on Endari® Accepted for Poster Presentation at the 63rd American Society of Hematology Annual Meeting & Exhibition
During the period, the stock managed to clock gains of as much as 10% and as it happens, the commercial stage biopharmaceutical firm was in the news on Monday as well. Emmaus is best known for its work on sickle cell disease and is regarded as a leader in that space. Yesterday, the company came into focus after it announced that the data for its product Endari is going to be presented at the 3rd American Society of Hematology (ASH) Annual Meeting and Exhibition.
The product in question is an oral powder and is meant for treating those who suffer from sickle cell disease. It goes without saying that it is a significant development for the company as it is going to be able to showcase its product in a key industry event. The event is going to be start on December 11 and continue up until December 14 at the Georgia World Congress Center located in the city of Atlanta in Georgia.
Traders Corner
EMMA stock has a pivot point at $1.46. Key supports for the stock are 1.1433, 1.2267, 1.3833 and resistances are 1.6233, 1.7067, 1.8633. Moreover, RSI stands at 52.
